[27G-pm] 医薬品設計・構造活性相関②

Fri. Mar 27, 2020 3:33 PM - 5:09 PM [Room G] Room G (1F)

Chair: Shinya Fujii, Yohei Soma

+Add all to schedule

3:33 PM - 3:45 PM

[27G-pm09] Identification of nobel human peroxisome proliferator-activated receptor alpha-selective agonists and its structural development

○Hiroyuki Miyachi¹, kazuto nunomura², bangzhong lin², takefumi doi², keisuke tachibana² (1. Lead Exploration Unit, Drug Discovery Initiative, Tokyo Univ. , 2. Grad. Sci. Pharm. Sci., Osaka Univ)

3:45 PM - 3:57 PM

[27G-pm10] Comprehensive understanding of structure-activity relationship of farnesoid X receptor (FXR) antagonists: Evaluation of pharmacokinetics profile and distribution toward the target tissues.

○Arisa Masuda¹, Yukiko Yamashita², Yusuke Iguchi², Keisuke Oda², Ko Fujimori³, Keigo Gohda⁴, Naoki Teno¹ (1. Grad. Sch. Pharm Sci., Hiroshima International Univ., 2. Fac. Pharm. Sci., Hiroshima International Univ., 3. Fac. Pharm Sci, Osaka Univ. Pharm. Sci., 4. CAMM-Kansai)

3:57 PM - 4:09 PM

[27G-pm11S] Development of LXR degradation inducers

○kanako Nemoto^1,2, Genichiro Tsuji¹, Nobumichi Ohoka¹, Mikihiko Naito¹, Yosuke Demizu^1,3 (1. NIHS, 2. Coll. of Bioresour. Sci., Nihon Univ., 3. Grad. Sch. of Med. Life Sci., Yokohama city Univ.)

4:09 PM - 4:21 PM

[27G-pm12] Degradation of pathogenic proteins using ISAAC

○Koushi Hidaka^1,2, Keiko Hojo^1,2, Yuko Tsuda^1,2 (1. Faculty of Pharm. Sci., Kobe Gakuin Univ., 2. Center for Life Sci., Kobe Gakuin Univ.)

4:21 PM - 4:33 PM

[27G-pm13] Development of a functional inhibitor for HIV-1 capsid

○Miyuki Nakayama¹, Takuya Kobayakawa¹, Masaki Kurakami¹, Sayaka Boku¹, Masaru Yokoyama², Tsutomu Murakami³, Moemi Kaneko¹, Osamu Kotani², Hironori Sato², Kohei Tsuji¹, Hirokazu Tamamura¹ (1. Institute of Biomaterials and Bioengineering (IBB), Tokyo Medical and Dental University (TMDU), 2. Laboratory of Viral Genomics, Pathogen Genomics Center, National Institute of Infectious Diseases, 3. AIDS Research Center, National Institute of Infectious Diseases)

4:33 PM - 4:45 PM

[27G-pm14S] Structure-activity relationship of small molecule inhibitor MKN-1A for HIV-1 capsid

○Sayaka Boku¹, Takuya Kobayakawa¹, Masaki Kurakami¹, Miyuki Nakayama¹, Masaru Yokoyama², Tsutomu Murakami³, Moemi Kaneko¹, Osamu Kotani², Hironori Sato², Kohei Tsuji¹, Hirokazu Tamamura¹ (1. Institute of Biomaterials and Bioengineering (IBB), Tokyo Medical and Dental University (TMDU), 2. Laboratory of Viral Genomics, Pathogen genomics Center, National Institute of Infection Diseases, 3. AIDS Research Center, National Institute of Infection Diseases)

4:45 PM - 4:57 PM

[27G-pm15S] Development of protein kinase C activators for cure of HIV infectious diseases

○Takahiro Ishii¹, Takuya Kobayakawa¹, Kouki Matsuda², Kazuhisa Yoshimura³, Kohei Tsuji¹, Hiroaki Mitsuya^2,4, Kenji Maeda², Hirokazu Tamamura¹ (1. Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2. National Center for Global Health and Medicine Research Institute, 3. Institute of Public Health, Bureau of Social Welfare and Public Health, Tokyo Metropolitan Government, 4. Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health)

4:57 PM - 5:09 PM

[27G-pm16S] Development of multi-targeting pyridinium-type C₆₀ derivatives for treating HIV/HCV co-infection

○Toi Kobayashi¹, Kyoko Takahashi¹, Shigeo Nakamura², Tomoyuki Ohe¹, Tadahiko Mashino¹ (1. Faculty of Pharmacy, Keio University, 2. Nippon Medical School)

Session information